TriangleEpcoritamab (NCT06919939)
Epcoritamab trial for Large B-cell Lymphoma (NCT06919939). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with eligible large B-cell lymphomas relapsed or refractory after treatment including anti-CD20 and anthracycline therapy. Previous CD19 CAR-T, CD20/CD3 bispecific treatment or stem-cell transplant is excluded.
The idea: epcoritamab links T-cells to CD20-bearing lymphoma cells; loncastuximab delivers a DNA-damaging payload to CD19-bearing cells. Patients receive epcoritamab injections with step-up dosing and loncastuximab infusions during four cycles, then eight epcoritamab-only cycles. Cycle lengths change. Researchers assess immune, neurologic, liver and fluid-retention toxicities.
This phase 2 study plans 26 patients. Juan Alderuccio leads at the University of Miami’s recruiting site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.